Effectiveness And Safety Of Reduced Dose Non-Vitamin K Antagonist Oral Anticoagulants In Patients Without Severe Renal Impairment
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has been a major advance for stroke prevention in atrial fibrillation. Because NOACs have significant renal clearance, dose reduction is needed in patients with severe kidney disease. However, some physicians may prescribe reduced-dose NOACs to patients with relatively good renal function due to the concerns over the bleeding risk. We sought to investigate the use and clinical outcomes of reduced-dose NOACs in patients without severe renal impairment.
Source: Value in Health - Category: Global & Universal Authors: X. Yao, N.D. Shah, L.R. Sangaralingham, B.J. Gersh Source Type: research
More News: Atrial Fibrillation | Bleeding | Health | International Medicine & Public Health | Stroke | Urology & Nephrology | Vitamin K | Vitamins